ArriVent BioPharma, Inc. Common Stock (AVBP) Fundamental Analysis: Bull vs. Bear Case

AVBP

ArriVent BioPharma, Inc. Common Stock

Fundamental data last updated:June 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/10/2026

Business Summary

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

VALUATION

P/E

-8.37

Market Cap ($M USD)

$1.26B

Forward P/E

8.14 PEG

0.04 PRICE TO SALES

0.00 PRICE TO BOOK

3.75 EV / EBITDA

-7.89

5-Year Average P/E

Free Cash Flow Yield

-10.71%

DCF Value

$1.05

Graham Number

N/A

Price to FCF

-9.34

EV to FCF

-8.88

Earnings Yield

-11.95%

FCF Yield

-10.71%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.22

Next Year EPS Growth Estimate

$3.31

Next Year Revenue Growth Estimate

$43.39B

Return on Equity (ROE)

-48.98%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00 Piotroski F-Score

1 Altman Z-Score

27.59 Return on Invested Capital (ROIC)

-48.37%

Current Ratio

13.95 Quick Ratio

13.95 Net Debt to EBITDA

0.41 Interest Coverage

0.00 Gross Profit margin

0.00%

FCF PER SHARE

$-2.98

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

AVBP ArriVent BioPharma, Inc. presents a perplexing valuation scenario. Despite a staggering Altman Z-score of 29.34, indicating robust financial health, the stock’s market price has been trading significantly below its DCF value. The Forward P/E of 8.32 suggests potential growth, yet the negative Earnings Yield of -14.66% raises concerns about profitability. The market seems to be pricing in a turnaround, but the negative ROIC of -57.79% and a Piotroski F-Score of 1 hint at operational inefficiencies. Investors must weigh these contradictions carefully.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, AVBP stands at the crossroads of innovation and adaptation. The company's ability to integrate AI-driven research and development could be pivotal in maintaining its competitive edge. As the industry embraces technological advancements, AVBP's positioning will be crucial for future growth.

The Bull Case

For the optimistic investor, AVBP offers a compelling narrative. The Forward PEG ratio of 0.046 indicates undervaluation relative to expected growth, while the negligible Debt/Equity ratio underscores financial prudence. Despite a negative FCF Yield, the high Current Ratio of 12.83 suggests liquidity strength. These metrics paint a picture of a company with potential pricing power and capital efficiency, poised for a turnaround.

The Bear Case

However, the bear case is hard to ignore. The negative Price to FCF of -8.52 and the Price/Book ratio of 3.69 suggest overvaluation concerns. With the stock trading close to its 52-week high, technical overextension is a risk. The lack of profitability, highlighted by a negative EPS and zero gross profit margin, further exacerbates the structural weaknesses. Investors should be wary of these red flags.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$45.00

Institutional Ownership %

1-Year Beta

1.52 Insider Buying % (6 Mo)

Distance to 52-Week High

19.17%

Distance to 52-Week Low

40.30%

EARNINGS SURPRISE %

-9.09%

50-DAY SMA

$27.13

200-DAY SMA

$22.53

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.